Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation

Europace

Volumn 10, Issue 8, 2008, Pages 961-966

  Shimano, Masayuki ^a   Inden, Yasuya ^a   Tsuji, Yukiomi ^b   Kamiya, Hiromi ^a   Uchikawa, Tomohiro ^a   Shibata, Rei ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Ablation; Arrhythmia; Atrium; Homocysteine

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; STATIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER ABLATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; INFORMATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR TACHYCARDIA;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CATHETER ABLATION; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 48749123710     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun140     Document Type: Article

References (42)

1. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
2. Haissaguerre M, Jais P, Shah DC, Garrigue S, Takahashi A, Lavergne T et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000;101:1409-17.
3. O'Neill MD, Jais P, Hocini M, Sacher F, Klein GJ, Clementy J et al. Catheter ablation for atrial fibrillation. Circulation 2007;116:1515-23.
4. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-3.
5. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83.
6. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
7. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999;82:448-54.
8. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001;85:153-8.
9. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-7.
10. Herrmann M, Taban-Shoma O, Hubner U, Pexa A, Kilter H, Umanskaya N et al. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin Chem 2007;53:773-80.
11. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL et al. Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology 2007;107:178-84.
12. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003;34:1258-61.
13. Marcucci R, Betti I, Cecchi E, Poli D, Giusti B, Fedi S et al. Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J 2004;148:456-61.
14. Loffredo L, Violi F, Fimognari FL, Cangemi R, Sbrighi PS, Sampietro F et al. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica 2005;90:1205-11.
15. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
16. McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol 2004;44:475-95.
17. Tziakas DN, Chalikias GK, Papanas N, Stakos DA, Chatzikyriakou SV, Maltezos E. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 2007;9:589-96.
18. Takahashi N, Imataka K, Seki A, Fujii J. Left atrial enlargement in patients with paroxysmal atrial fibrillation. Jpn Heart J 1982;23:677-83.
19. Sundstrom J, Sullivan L, D'Agostino RB, Jacques PF, Selhub J, Rosenberg IH et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension 2003;42:1100- 5.
20. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL et al. Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology 2007;107:178-84.
21. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26.
22. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
23. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
24. Anne W, Willems R, Holemans P, Beckers F, Roskams T, Lenaerts I et al. Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 2007;43:148-58.
25. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 2004;43:818-25.
26. Laurent G, Moe G, Hu X, Holub B, Leong-Poi H, Trogadis J et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 2008;67:705-13.
27. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-14.
28. Moshal KS, Singh M, Sen U, Rosenberger DS, Henderson B, Tyagi N et al. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 2006;291:H2825-H2835.
29. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-52.
30. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62.
31. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004;109:363-8.
32. Sen U, Moshal KS, Tyagi N, Kartha GK, Tyagi SC. Homocysteine-induced myofibroblast differentiation in mouse aortic endothelial cells. J Cell Physiol 2006;209:767-74.
33. Cai BZ, Gong DM, Liu Y, Pan ZW, Xu CQ, Bai YL et al. Homocysteine inhibits potassium channels in human atrial myocytes. Clin Exp Pharmacol Physiol 2007;34:851-5.
34. Fareh S, Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999;100:2191-7.
35. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000;102:2463-5.
36. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002;15:157-63.
37. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
38. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
39. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
40. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007;8:17-31.
41. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology 1999;92:21-7.
42. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.